Anticipating the introduction of stringent new EC legislation on dioxin-like PCBs this month, Croda Health Care announced that it is strengthening its purity position for its Incromega omega-3 concentrates. The company said it now certifies dioxin-like PCB levels for each batch of Incromega, with maximum limits more than 60% below EC legislative requirements. Croda’s Incromega lipids, manufactured using PureMax technology, offer high potency EPA and DHA concentrates with dioxin-like PCB levels of below 3 pg WHO-TEQ/g against EC purity standards of 8 pg WHO-TEQ/g. The company’s rigorous analytical program includes analysis and certification of every batch of Incromega for environmental pollutants such as dioxin-like PCBs, dioxins and furans, and PAHs.
Steve Mellor, Technical Manager, commented: “We have invested heavily in environmental testing to support our leading position in omega-3 purity. This alleviates the burden of expensive and time-consuming testing for our customers. Our unique PureMax technology is key to minimising impurity levels and we continue to work closely with industry partners to drive forward purity standards.”
PureMax is the company’s proprietary purification and concentration technology for omega-3 lipids. Using a minimum of three molecular distillation steps, the process minimises heavy metals, environmental pollutants and oxidative impurities to ensure the highest quality products. Manufacturing to GMP standards at Croda’s expanded facility in the UK, PureMax also selectively concentrates EPA and/or DHA to provide high potency, biologically active omega-3 lipids.
The health benefits of long-chain polyunsaturated fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are well known. Oily fish offer excellent sources of EPA and DHA, however, recent news stories have raised concerns about the levels of environmental contaminants found in certain fish. Croda’s Incromega concentrates offer a solution by providing high levels of EPA and DHA in ultra-pure form.
Dioxin-like PCBs, dioxins, furans and PCBs are organic pollutants from industrial processes. Background levels are found throughout the world in practically all media including soil, water and food. Consumption of these organic pollutants above safe levels over a lifetime may result in an increased risk of cancer.
Croda’s Incromega lipid concentrates offer enhanced bioavailability and potency for specific consumer health concerns including heart, joint, maternal, skin health, brain and eye health.
Croda Health Care is a key marketing division of Croda International plc, the UK-based manufacturer of speciality ingredients for the global consumer and health care markets. Providing naturally-derived, high quality actives and excipients for pharmaceutical, nutritional and animal health markets, the Health Care division focuses on delivering condition and application-specific solutions to meet the stringent technical, quality and market requirements of these industries. The company's extensive range of health care ingredients includes essential fatty acids, high purity lipids, drug delivery systems and protein derivatives. Globally Croda International plc had sales of £305.6m (€455.7m) in 2005, and recorded a pre-tax trading profit of £49.2m (€73.4m) for continuing operations.
1) European Commission – EC (February 2006) amending regulation No 466/2001 Setting maximum levels for certain contaminants in foodstuffs as regards dioxins and dioxin-like PCBs Commission Regulation No 199/2006